Last reviewed · How we verify
LON002
At a glance
| Generic name | LON002 |
|---|---|
| Sponsor | LondonPharma Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours (PHASE1, PHASE2)
- An Extension Study of LON002 in Patients With Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LON002 CI brief — competitive landscape report
- LON002 updates RSS · CI watch RSS
- LondonPharma Ltd. portfolio CI